Should I buy or sell PAVmed stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PAVM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAVM, but not buy additional shares or sell existing shares. View PAVM analyst ratings or view top-rated stocks .

What is PAVmed's stock price target for 2024?

1 analysts have issued 12-month price targets for PAVmed's shares. Their PAVM share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 976.9% from the stock's current price. View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts .

How have PAVM shares performed in 2024?

PAVmed's stock was trading at $4.12 at the beginning of the year. Since then, PAVM shares have decreased by 52.7% and is now trading at $1.95. View the best growth stocks for 2024 here .

When is PAVmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PAVM earnings forecast .

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) announced its earnings results on Tuesday, March, 26th. The company reported ($1.57) earnings per share for the quarter. The business earned $1.05 million during the quarter.

When did PAVmed's stock split?

Shares of PAVmed reverse split on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of PAVmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) , Co-Diagnostics (CODX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Cidara Therapeutics (CDTX) , Catalyst Pharmaceuticals (CPRX) , Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP) .

How do I buy shares of PAVmed?

Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PAVM

PAVmed (PAVM) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PAVM Stock Alerts

$1.95

0.00 (0.00%)

(As of 12:34 PM ET)

Compare

Today's Range: $1.87
▼
$2.00
50-Day Range: $1.82
▼
$3.08
52-Week Range: $1.60
▼
$9.36

Volume: 11,372 shs
Average Volume: 66,707 shs
Market Capitalization: $17.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get PAVmed alerts:

PAVmed MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 976.9% Upside
$21.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.61
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

Medical Sector

638th out of 918 stocks

Surgical & Medical Instruments Industry

72nd out of 97 stocks

3.0

Analyst's Opinion

Consensus Rating
PAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
PAVmed has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PAVM.

0.0

Dividend Strength

Dividend Yield
PAVmed does not currently pay a dividend.
Dividend Growth
PAVmed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
PAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.
Environmental Sustainability
The Environmental Impact score for PAVmed is -0.78.

3.1

News and Social Media Coverage

News Sentiment
PAVmed has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for PAVmed this week, compared to 1 article on an average week.
Search Interest
8 people have searched for PAVM on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
MarketBeat Follows
3 people have added PAVmed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PAVmed insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.60% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 19.93% of the stock of PAVmed is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of PAVmed is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PAVmed is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About PAVmed Stock (NASDAQ:PAVM)

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

PAVM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PAVM Stock News Headlines

April 18, 2024 | americanbankingnews.com

PAVmed (NASDAQ:PAVM) Share Price Crosses Below 50-Day Moving Average of $2.19

April 17, 2024 | msn.com

PAVmed (PAVM) Price Target Decreased by 8.51% to 10.97

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization

March 29, 2024 | seekingalpha.com

PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for PAVmed with Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

March 28, 2024 | finance.yahoo.com

Q4 2023 PAVmed Inc Earnings Call

March 27, 2024 | finance.yahoo.com

PAVmed Full Year 2023 Earnings: EPS Beats Expectations

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 26, 2024 | prnewswire.com

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

March 25, 2024 | markets.businessinsider.com

What Wall Street expects from PAVmed's earnings

March 25, 2024 | tmcnet.com

Novosound secures patent for wireless wearable ultrasound imaging platform

March 21, 2024 | prnewswire.com

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

March 21, 2024 | prnewswire.com

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

March 13, 2024 | prnewswire.com

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

March 12, 2024 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

March 2, 2024 | morningstar.com

PAVmed Inc PAVM

February 29, 2024 | finance.yahoo.com

PAVmed Inc.'s (NASDAQ:PAVM) Intrinsic Value Is Potentially 66% Above Its Share Price

February 22, 2024 | benzinga.com

PAVmed Stock (NASDAQ:PAVM) Dividends: History, Yield and Dates

February 16, 2024 | finance.yahoo.com

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

February 16, 2024 | prnewswire.com

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

February 15, 2024 | prnewswire.com

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

February 10, 2024 | msn.com

PAVmed Inc. Grants Shareholders Lucid Diagnostics Dividend

February 8, 2024 | finance.yahoo.com

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

January 18, 2024 | finance.yahoo.com

What Does PAVmed Inc.'s (NASDAQ:PAVM) Share Price Indicate?

December 16, 2023 | msn.com

PAVmed (PAVM) Price Target Increased by 685.71% to 21.04

December 11, 2023 | finance.yahoo.com

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders

See More Headlines

Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PAVM
CUSIP: N/A
CIK: 1624326
Web: www.pavmed.com
Phone: (212) 949-4319
Fax: N/A
Employees: 107
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $21.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +976.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.3264)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,180,000.00
Net Margins: -2,617.25%
Pretax Margin: -3,232.59%
Return on Equity: N/A
Return on Assets: -85.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.45
Quick Ratio: 0.45

Sales & Book Value

Annual Sales: $2.45 million
Price / Sales: 7.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.35) per share
Price / Book: -0.58

Miscellaneous

Outstanding Shares: 9,170,000
Free Float: 8,016,000
Market Cap: $17.88 million
Optionable: Optionable
Beta: 0.85

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Lishan Aklog M.D. (Age 58)
Chairman & CEO
Comp: $945.09k
Mr. Dennis M. McGrath CPA (Age 67)
President, CFO & Corporate Secretary
Comp: $663.38k
Mr. Shaun M. O'Neill M.B.A. (Age 41)
Executive VP & COO
Comp: $447.47k
Dr. Brian J. deGuzman M.D. (Age 59)
Executive VP, Chief Technology & Compliance Officer
Comp: $427.6k
Dr. Suman M. Verma M.D.
Ph.D., Senior VP of Molecular Genetics & Chief Scientific Officer
Michael Parks
Vice President of Investor Relations
Mr. Michael Adam Gordon (Age 50)
Executive VP, General Counsel & Secretary
Dr. Deepika A. Lakhani Ph.D.
Senior VP, Chief Regulatory & Quality Officer
Dr. Victoria T. Lee M.D.
Senior VP & Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PAVM Stock Analysis - Frequently Asked Questions

Should I buy or sell PAVmed stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PAVM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAVM, but not buy additional shares or sell existing shares.
View PAVM analyst ratings or view top-rated stocks.
What is PAVmed's stock price target for 2024?: 1 analysts have issued 12-month price targets for PAVmed's shares. Their PAVM share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 976.9% from the stock's current price.
View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts.
How have PAVM shares performed in 2024?: PAVmed's stock was trading at $4.12 at the beginning of the year. Since then, PAVM shares have decreased by 52.7% and is now trading at $1.95.
View the best growth stocks for 2024 here.
When is PAVmed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our PAVM earnings forecast.

How were PAVmed's earnings last quarter?: PAVmed Inc. (NASDAQ:PAVM) announced its earnings results on Tuesday, March, 26th. The company reported ($1.57) earnings per share for the quarter. The business earned $1.05 million during the quarter.
When did PAVmed's stock split?: Shares of PAVmed reverse split on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of PAVmed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP).
How do I buy shares of PAVmed?: Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PAVM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PAVmed (PAVM) Stock Price, News & Analysis

PAVmed MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About PAVmed Stock (NASDAQ:PAVM)

PAVM Stock Price History

PAVM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PAVM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™